NasdaqGM:TRVIPharmaceuticals
Trevi Therapeutics (TRVI): Assessing Valuation as Analyst Coverage Highlights Haduvio’s Potential in Chronic Cough Market
What’s Behind the Buzz With Trevi Therapeutics?
Trevi Therapeutics (TRVI) is in the spotlight this week after Morgan Stanley initiated coverage, calling attention to the company’s lead drug candidate, Haduvio, for chronic cough. The move by a major investment bank has prompted many investors to sit up and pay closer attention, especially given recent big pharma partnerships in the chronic cough space. With Haduvio positioned as a potential solution for an underserved market, there is growing...